This session includes a discussion of ongoing research in radiopharmaceuticals with emphasis in prostate cancer. It provides an overview of the mechanism of action of radioligands, and the theranostic approach in oncology. The discussion highlights the logistics of radiopharmaceutical implementation in a clinical setting.
